Phaseline

Targets › CALCRL

CALCRL (Calcitonin gene-related peptide type 1 receptor): drug programs, companies and trials

5 programs from 3 companies in 24 trials: 12 Phase 3, 5 Phase 4, 4 Phase 1, 3 Phase 2; Neurology, Other, Oncology; next expected readout Nov 2026.

G protein-coupled receptor which specificity is determined by its interaction with receptor-activity-modifying proteins (RAMPs). Together with RAMP1, form the receptor complex for calcitonin-gene-related peptides CALCA/CGRP1 and CALCB/CGRP2. (UniProt, Q16602)

Open in Phaseline: the race on CALCRL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerRimegepant
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 4Acute Treatment of Migraine; Menstrual Migraine; Preventive Treatment of Migraine; Pediatric Migraine …Nov 2026
AmgenErenumab
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 3Migraine; Posttraumatic Headache; SchwannomatosisNov 2026
AbbVieUbrogepant
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 3Migraine; Healthy VolunteerMay 2027
AbbVieAtogepant
Calcitonin gene-related peptide type 1 receptor antagonist
CALCRLPhase 3Menstrual Migraine (MM); Episodic Migraine; Chronic MigraineJul 2027
PfizerZavegepant (PF-07930207)
Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist
RAMP1, CALCRLPhase 1Acute Treatment of Migraine; MigraineAug 2027

Conditions

Migraine (9) Acute Treatment of Migraine (4) Vestibular Migraine (2) Menstrual Migraine (MM) (1) Episodic Migraine (1) Chronic Migraine (1) Menstrual Migraine (1) Preventive Treatment of Migraine (1) Pediatric Migraine (1) Healthy Volunteer (1) Posttraumatic Headache (1) Schwannomatosis (1)

Modalities

small molecule (4), antibody (1)

Companies

AbbVie (2) Pfizer (2) Amgen (1)

Related targets

RAMP1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.